MedPath
Found 16 clinical trials|View Analysis
Sort by:

COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.

Phase 1
Withdrawn
Conditions
Healthy
First Posted Date
2015-03-23
Last Posted Date
2020-09-18
Lead Sponsor
Pharmaceutical Research Unit, Jordan
Registration Number
NCT02395237
Locations
🇯🇴

Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan

Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2014-09-30
Last Posted Date
2017-01-24
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
532
Registration Number
NCT02252965
Locations
🇩🇪

Please contact the Merck KGaA Communication Center, Darmstadt, Germany

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: EFB0026 (metformin immediate-release)
Drug: EFB0027 (metformin delayed release)
First Posted Date
2012-09-03
Last Posted Date
2016-09-20
Lead Sponsor
Elcelyx Therapeutics, Inc.
Target Recruit Count
24
Registration Number
NCT01677299
Locations
🇺🇸

Celerion, Inc., Lincoln, Nebraska, United States

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

First Posted Date
2012-07-20
Last Posted Date
2016-06-22
Lead Sponsor
AstraZeneca
Target Recruit Count
320
Registration Number
NCT01646320
Locations
🇺🇸

Torrance Clinical Research Institute Inc., Lomita, California, United States

🇺🇸

Diabetes Medical Center Of California, Northridge, California, United States

🇺🇸

Cassidy Medical Group/Clinical Research Advantage, Vista, California, United States

and more 25 locations

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Phase 1
Terminated
Conditions
Type 2 Diabetes Mellitus
Interventions
First Posted Date
2012-02-02
Last Posted Date
2015-06-22
Lead Sponsor
AstraZeneca
Target Recruit Count
4
Registration Number
NCT01525225
Locations
🇺🇸

Childrens Hospital Of Pittsburgh Of Upmc, Pittsburgh, Pennsylvania, United States

🇺🇸

Promedica Toledo Children'S Hospital, Toledo, Ohio, United States

🇺🇸

Axis Clinical Trials, Los Angeles, California, United States

and more 4 locations

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
First Posted Date
2012-01-26
Last Posted Date
2012-08-29
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
64
Registration Number
NCT01518712

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Canagliflozin tablets
Drug: Metformin IR tablets
Drug: Canagliflozin/metformin IR FDC tablets
First Posted Date
2012-01-11
Last Posted Date
2013-01-31
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
64
Registration Number
NCT01508195

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Canagliflozin tablets
Drug: Metformin IR tablets
Drug: Canagliflozin/metformin IR FDC tablets
First Posted Date
2012-01-11
Last Posted Date
2013-01-16
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
64
Registration Number
NCT01508182
© Copyright 2025. All Rights Reserved by MedPath